Atezolizumab and Bevacizumab in EGFR Mutant NSCLC in Patients With Progressive Disease After Receiving Osimertinib
Clinical trial NCT04099836 · TERMINATED
Trial details
- NCT number
- NCT04099836
- Sponsor
- Duke University
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-07-09
- Primary completion
- 2022-11-13
- Enrollment
- 7
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.